Holen Sie sich die Stockscreener-App
3.78
3.32%
-0.13
Handel nachbörslich:
3.80
0.02
+0.53%
Schlusskurs vom Vortag:
$3.91
Offen:
$3.91
24-Stunden-Volumen:
1.60M
Relative Volume:
1.37
Marktkapitalisierung:
$251.47M
Einnahmen:
$488.00K
Nettoeinkommen (Verlust:
$-41.44M
KGV:
-4.0645
EPS:
-0.93
Netto-Cashflow:
$-31.47M
1W Leistung:
-8.25%
1M Leistung:
+21.94%
6M Leistung:
+6.78%
1J Leistung:
+60.85%
1-Tages-Spanne:
$3.73
$3.97
1-Wochen-Bereich:
$3.73
$4.555
52-Wochen-Spanne:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Vergleichen Sie CRDF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
3.78 | 274.09M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-06-24 | Eingeleitet | Jefferies | Hold |
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Cardiff Oncology Inc. Stock Analysis and ForecastTriple-digit growth rates - Autocar Professional
Is Cardiff Oncology Inc. a good long term investmentUnprecedented profits - Autocar Professional
What analysts say about Cardiff Oncology Inc. stockExceptional stock performance - jammulinksnews.com
What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser
What drives Cardiff Oncology Inc. stock priceOverwhelming financial success - jammulinksnews.com
Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha
How Cardiff Oncology Inc. stock performs during market volatilityHigh Return Setup Scanner - Newser
Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
International Business Times - FinancialContent
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Cardiff Oncology Holds Annual Stockholders Meeting 2025 - TipRanks
Jefferies Initiates Coverage on Cardiff Oncology (CRDF) with Hol - GuruFocus
Cardiff Oncology (CRDF) Begins Coverage With Hold Rating from Jefferies | CRDF Stock News - GuruFocus
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com
Market Overreaction to Cardiff Oncology's Data Delay Presents a Rare Buying Opportunity - AInvest
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
Cardiff Oncology falls after naming new medical chief ahead of key trial readout - MSN
CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus
Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus
Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener
Cardiff Oncology stock falls as new medical chief named (CRDF) - Seeking Alpha
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical - GlobeNewswire
Cardiff Oncology Names New Chief Medical Officer - marketscreener.com
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer - Investing.com
Bank of America Corp DE Sells 11,352 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology's Leadership Shift and Clinical Catalysts: A New Chapter for Onvansertib? - AInvest
Big Cuts to U.S. Cancer Research May Create Historic Opening for Biotech Investors - Baystreet.ca
Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):